Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Recordati Pharmaceuticals signs TransAct LAT deal with Amdipharm

Recordati Pharmaceuticals signs TransAct LAT deal with Amdipharm

14th July 2009

Recordati Pharmaceuticals has signed a deal with international pharmaceutical group Amdipharm for the sales and marketing rights to TransAct local action transcutaneous (LAT) in a number of regions.

In a statement, the organisation explained that TransAct LAT is a transdermal patch that contains 40 mg of flurbiprofen, which is a widely prescribed non-steroidal anti-inflammatory drug.

TransAct LAT is used for the relief of pain relating to the musculoskeletal system.

The company said: “Recordati has an established franchise in pain and inflammation management and the addition of this product provides a valid further choice for the medical practitioner.”

Founded in 2002, Amidpharm has a portfolio of more than 60 products, which it states generate sales in more than 100 countries around the world.

Earlier this month, Recordati Pharmaceuticals announced that its Arrigo Recordati international prize for scientific research has been awarded to Valentin Fuster, director of the Mount Sinai Heart facility in New York.

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.